VitaSpring Biomedical

VitaSpring Biomedical is a clinical-stage biotechnology company dedicated to developing innovative therapies for aging-related diseases, with a primary focus on neurodegenerative and inflammatory conditions. Founded by esteemed scientists Dr. Xiaodong Wang and Dr. Zhiyuan Zhang, the company leverages advanced insights into programmed cell death and cell stress response pathways. Its lead program, VR742, is a highly potent and selective small molecule RIPK1 inhibitor designed to cross the blood-brain barrier for the treatment of Amyotrophic Lateral Sclerosis (ALS). VitaSpring operates a global R&D model with facilities in both Beijing and the United States to accelerate the translation of foundational biological research into clinical candidates. The company is backed by a robust syndicate of international investors and aims to address significant unmet needs in the global aging population.